Focus Partners Wealth
REGN icon

Focus Partners Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Focus Partners Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.7M Buy
16,441
+4,535
+38% +$3.47M 0.01% 640
2025
Q4 		$9.19M Buy
11,906
+2,754
+30% +$1.87M 0.01% 728
2025
Q3 		$5.15M Buy
9,152
+3,785
+71% +$2.14M 0.01% 735
2025
Q2 		$2.82M Sell
5,367
-579
-10% -$323K 0.01% 813
2025
Q1 		$3.77M Sell
5,946
-3,280
-36% -$2.26M 0.01% 707
2024
Q4 		$6.57M Buy
9,226
+6,255
+211% +$5.25M 0.02% 552
2024
Q3 		$3.12M Sell
2,971
-3,922
-57% -$4.36M 0.01% 673
2024
Q2 		$7.25M Buy
6,893
+1,900
+38% +$1.84M 0.02% 427
2024
Q1 		$4.81M Buy
4,993
+2,319
+87% +$2.21M 0.04% 328
2023
Q4 		$2.35M Buy
+2,674
New +$2.2M 0.03% 328

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Focus Partners Wealth's REGN Position: Q1 2026 in Review

Focus Partners Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 38% in Q1 2026, buying an estimated $3.47M and bringing the position to 16,441 shares worth $12.7M. The position accounts for 0.01% of the portfolio, ranked #640.

Focus Partners Wealth first reported a position in REGN in Q4 2023 and has held it in 10 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Focus Partners Wealth held 16,441 shares of Regeneron Pharmaceuticals worth $12.7M as of Q1 2026.
  • Focus Partners Wealth bought 4,535 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.47M.
  • Regeneron Pharmaceuticals made up 0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #640 holding.
  • Focus Partners Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.